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OBJECTIVE: To evaluate the effects of three different target-controlled remifentanil infusion rates during target-
controlled propofol infusion on hemodynamic parameters, pain, sedation, and recovery score during oocyte
retrieval.
METHODS: Sixty-nine women were scheduled for oocyte retrieval. Target-controlled propofol infusion at an effect-
site concentration of 1.5 mg/mL was instituted. The patients were randomly allocated to receive remifentanil at an
effect-site concentration of either 1.5 (group I, n=23), 2 (group II, n=23) or 2.5 ng/mL (group III, n=23).
Hemodynamic variables, sedation, pain, the Aldrete recovery score, and side effects were recorded.
RESULTS: Hemodynamic variables, sedation and pain scores and the number of patients with the maximum Aldrete
recovery score 10 min after the procedure were comparable among the groups. The number of patients in group III
with the maximum Aldrete recovery score 5 min after the procedure was significantly lower than that in groups I
and II. One patient in group II and one patient in group III suffered from nausea.
CONCLUSION: Similar pain-free conscious sedation conditions without significant changes in hemodynamic
parameters were provided by all three protocols. However, target controlled infusion of remifentanil at 1.5 or 2 ng/
mL proved superior at providing early recovery compared to 2.5 ng/mL.
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INTRODUCTION
Transvaginal ultrasound-guided oocyte retrieval is a
relatively painful assisted reproductive technology proce-
dure that is performed on an outpatient basis. To date, both
general and regional anesthetics, including paracervicals,
spinals and epidurals, have been used, and various methods
of conscious sedation and analgesia have been attempted.
1,2
Pain during oocyte retrieval is caused by a puncture of the
vaginal skin and the ovarian capsule, aspiration of the ovary
and manipulation of the ovary. Therefore, during sedation
and analgesia, the role of the anesthesiologist is, primarily,
to provide adequate pain relief to keep the patient imm-
obilized during critical times and, secondarily, to provide
sedation for anxious patients. Otherwise, bleeding from the
puncture site and into the abdomen after oocyte retrieval
can lead to hospital admission.
1
Whenever favorable analgesia with sedation and rapid
recovery are desired, propofol and remifentanil are the
agents of choice in ambulatory settings due to their
pharmacokinetic profile.
3 In contrast, target-controlled infu-
sion (TCI) is a popular system that maintains a particular
target plasma drug concentration using standard pharmaco-
kinetic equations.
4,5 Although TCI has been used in many
different kinds of outpatient procedures,
6-10 few studies of its
use during oocyte retrieval have yet been reported.
11-13 To
our knowledge, the dose-effect relationship of TCI of
remifentanil and propofol in spontaneously breathing
women scheduled for oocyte retrieval has not been investi-
gated. Therefore, we aimed to evaluate the effects of three
different TCI protocols (including remifentanil and propofol)
on hemodynamic parameters, pain, sedation, the recovery
score, and side effects in patients undergoing oocyte retrieval
in a randomized prospective study.
METHODS
After obtaining approval from the ethics committee
and written informed consent from each patient, 69
unpremedicated women who had an American Society of
Anesthesiologists physical status class I or II, were between
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81121 and 45 years old, and were scheduled for oocyte retrieval
were enrolled. Before starting the procedure, the patients
were told to evaluate their pain according to a 10-point
numerical rating scale, where 0 corresponded to ‘‘no pain,’’
and 10 corresponded to the ‘‘worst possible pain.’’ Scores
between 0 and 3 were accepted as relatively pain-free. Upon
arrival to the anesthesia suite, intravenous infusion of
Ringer’s lactate (5 mL/kg/h) solution was started. Heart
rate, non-invasive blood pressure and peripheral oxygen
saturation (SpO2) were continuously monitored and fol-
lowed every minute for 5 minutes after induction and then
every 5 minutes until the end of the procedure. These
parameters were recorded prior to drug administration at
baseline (control), at the onset of the procedure (start), at the
time of puncture and aspiration of the oocytes from each
ovary (first and second puncture) and at the end of the
procedure. All of the patients received 4 L/min of oxygen
via a face mask.
Sedation levels were evaluated using a 5-point scale
(1, fully awake and oriented; 2, drowsy; 3, eyes closed,
responds promptly to verbal commands; 4, eyes closed, only
aroused upon mild physical stimulation; 5, eyes closed, not
aroused upon mild physical stimulation), as described by
Hong et al.
12 Sedation scores $3 were the target throughout
the procedure. Whenever a patient needed a TCI rate
adjustment (increase or decrease) for remifentanil, the
analgesia level (according to the numerical rating scale)
and the sedation score were recorded every 5 minutes until
the end of the procedure, particularly at the times when the
ovarian capsules were aspirated from each ovary. Acc-
ording to the preference of the gynecologists for standar-
dized procedures, the right ovarian puncture (called the first
puncture) was followed by the left ovarian puncture (called
the second puncture) in all of the patients.
Propofol and remifentanil were administered with a TCI
device (Orchestra Base PrimeaH, Fresenius Kabi, France),
which enables the drug concentration in the blood, in the
plasma (Cp) and at the effect site (Ce) to be continuously
controlled.
14 The device is a system that allows untagged
syringes to be used with generic, low-cost propofol. The
pharmacokinetic model described by Schnider et al.
5 uses
age as a co-variate to improve the accuracy of the model.
Because the model has a smaller-volume central compart-
ment and equilibrates more quickly with the effect site,
5 our
patients received TCI propofol driven by the Schnider
model with effect-site control. Meanwhile, the infusion rate
of TCI remifentanil was controlled by Minto’s pharmacoki-
netic model incorporated into software that was previously
used specifically for remifentanil.
4,7 Syringes containing 1%
propofol (10 mg/mL) and remifentanil (50 mg/mL) were
simultaneously loaded onto the device and connected to the
patient’s intravenous catheter using a three-way stopcock.
The patients were randomly allocated into 3 groups using
written and enclosed computer-generated group numbers
corresponding to the 3 different protocols: group I (n=23),
TCI remifentanil at Ce 1.5 ng/mL; group II (n=23), 2 ng/
mL; group III (n=23), 2.5 ng/mL. A constant rate of TCI
propofol at Ce 1.5 mg/mL at one of the three remifentanil
rates was started, depending on the group assignment. The
remifentanil rate was accordingly adjusted by incremental
increases or decreases of 0.5 mg/mL if the numerical rating
scale was greater than 3 or if the SpO2 was ,95%. The pro-
pofol and remifentanil infusions were discontinued after the
aspiration of the last follicle from the ovary. The total
amounts of remifentanil and propofol that were used were
then checked and noted. The duration of both the anesthesia
and the procedure were also recorded.
In the absence of bleeding from the puncture sites, the
patients were transferred to the recovery room. The Aldrete
recovery score, also known as the post-anesthesia recovery
score, was determined 5 and 10 minutes after the comple-
tion of the procedure.
15 According to the Aldrete recovery
score, the total maximum score is 10, and a score $9i s
required for discharge. Each aspect, including the activity
level, respiration, circulation, consciousness and oxygen
saturation (via SpO2), was scored between 0 and 2.
The postoperative nausea and vomiting scores (0, no
nausea and vomiting; 1, mild nausea, no treatment
requested; 2, nausea only, give anti-emetics as prescribed
until resolved; 3, vomiting, give anti-emetics as prescribed
until resolved; 4, nausea/vomiting that does not respond to
emetics) and side effects (such as dizziness, itching,
agitation and respiratory depression) were recorded by an
independent blinded observer who was unaware of the
selected TCI remifentanil rate. During post-anesthesia care,
Table 1 - Demographic data.
Group I (n = 23) Group II (n = 23) Group III (n = 23)
Age (yr) 33.0 ¡ 1.3 34.5 ¡ 1.1 34.6 ¡ 1.2
Weight (kg) 62.0 ¡ 2.2 64.9 ¡ 1.9 69.2 ¡ 3.0
Height (cm) 159.8 ¡ 1.6 159.9 ¡ 0.9 158.1 ¡ 4.5
Data are expressed as mean ¡ sem.
Figure 1 - Mean arterial pressure.
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812the patients suffering from postoperative nausea and
vomiting were treated with intravenous ondansetron
(8 mg). The patients were kept in the recovery room for at
least 30 minutes, and any patients who had Aldrete
recovery scores of 10 and were free from postoperative
nausea and vomiting were discharged.
Oral paracetamol (500 mg) was administered upon a
patient’s request for postoperative analgesia. The clinical
and ongoing pregnancy rates were obtained from the
records. Prior to their discharge, all of the women were
interviewed in the recovery room about their satisfaction
with the anesthetic technique and their pain after the
procedure .
Statistical analysis
A power analysis suggested that a minimum of 20 subjects
per group would be required to provide a power of 80% for
detecting a 20% change in the plasma remifentanil concen-
trationandintheamountofremifentanilduring spontaneous
respiration in patients undergoing oocyte retrieval. This
analysis was based on a previous study.
16 The data were
expressed as mean ¡ standard error of the mean (mean ¡
sem) or n (%), where appropriate. One-way analysis of
variance followed by a Bonferroni correction was performed
when comparing all of the continuous variables. The
categorical variables were analyzed using the 6
2 or Fisher’s
exact test, as appropriate. A p-value of less than 0.05 was
considered to be statistically significant.
RESULTS
The three groups were similar with respect to their
demographic data (Table 1).
The hemodynamic variables (including the mean arterial
pressure and heart rate) were comparable among the groups
(Figures 1 and 2).
The duration of both the anesthesia and the procedure
and the amount of propofol used with TCI were comparable
among the groups, but the amount of remifentanil used in
group III was significantly higher than in either group I or
II, as expected from the preselected study protocol (Table 1).
The need for an increase in the remifentanil rate was
observed in only 6 patients from group I, whereas none of
the patients from group II or III needed increase in rate
adjustments. However, we needed to decrease the remifen-
tanil rate in 2 patients from group II and in 5 patients from
group III (Table 2). These patients needed a jaw thrust
followed by brief periods of assisted mask ventilation. The
peripheral oxygen saturation measurements were also
comparable among the groups.
Five minutes after the procedure, the maximum Aldrete
recovery score (10) was achieved in 18 and 17 out of 23
patients from groups I and II, respectively. However, only 8
out of 23 patients in group III reached the maximum Aldrete
recovery score within 5 minutes. This number was
significantly lower compared to groups I and II. However,
10 minutes after the procedure, all of the patients in the
Figure 2 - Heart rate.
Table 2 - Data of anesthesia protocol and pregnancy rate.
Group I (n = 23) Group II (n = 23) Group III (n = 23)
Duration of anesthesia (min) 20.0 ¡ 1.8 17.3 ¡ 1.8 18.7 ¡ 1.6
Duration of the procedure (min) 11.7 ¡ 1.0 12.0 ¡ 1.4 14.6 ¡ 1.3
Total amount of propofol (mg) 121.9 ¡ 9.2 115.0 ¡ 10.3 134.1 ¡ 11.6
Total amount of remifentanil (mg) 108.7 ¡ 9.0 123.4 ¡ 10.2 164.1 ¡ 11.4*
Need for an increase in the TCI remifentanil rate
[n (%)]
6 (26) - -
Need for an decrease in the TCI remifentanil rate
[n (%)]
- 2 (9) 5 (22)
Patients with an Aldrete recovery score of 10 after
5 min [n (%)]
18 (78) 17 (73) 8 (35)*
Patients with an Aldrete recovery score of 10 after
10 min [n (%)]
23 (100) 23 (100) 23 (100)
Postoperative nausea and vomiting (n [%]) - 1 (4) 2 (9)
Pregnancy rate (n [%]) 10 (43) 10 (43) 12 (52)
Data are expressed as mean ¡ sem or n (%).
*P,0.05 vs. the other groups.
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813three groups had the maximum Aldrete recovery score of 10
(Table 2).
During the first30 minutes of follow-up, noneof thepatients
suffered from pain in the recovery room. In terms of the side
effects, 1 patient from group II and 2 patients from group III
suffered from postoperative nausea and vomiting (Table 2).
The clinical pregnancy rates were 43%, 43% and 52% in
groups I, II and III, respectively (Table 2).
The pain assessment and sedation scores did not differ
significantly among the groups (Table 3).
Sixty-six women who were free from postoperative
nausea and vomiting stated during the interview prior to
discharge that they were satisfied with their anesthetic care.
DISCUSSION
We demonstrated that the effects of the three different
protocols on hemodynamic parameters, sedation score, pain
score, recovery score recorded 10 minutes after the
procedure and side effects were similar. However, the
percentage of women with a recovery score of 10 recorded
5 minutes after the procedure was significantly lower in the
group receiving 2.5 ng/mL of TCI remifentanil with
propofol due to the significantly higher amount of remi-
fentanil in the preselected study protocol. Therefore, rates of
1.5 and 2 ng/mL of remifentanil during 1.5 mg/mL of
propofol seem to be superior to the remifentanil rate of
2.5 ng/mL at providing earlier recovery.
When conscious sedation with remifentanil infusion was
compared with conscious sedation with a paracervical block,
an extra benefit was not found, although the plasma
remifentanilconcentrationscalculatedbythesoftwareshowed
a significant decrease in the group receiving a paracervical
block and remifentanil.
16 Additionally, it has been reported
that the use of 50% oxygen/nitrous oxide via mask ventilation
with TCI propofol reduces the amount of propofol that is
required to prevent a response to oocyte retrieval in 50% of
women (compared to women receiving oxygen/air).
13
The target-controlled infusion system developed in the
last decade rapidly provides stable effect-site concentrations
that depend on the drug onset time and are maintained for
as long as they are desired because these devices deliver
intravenous drugs using a computer-controlled algorithm
that considers each drug’s particular pharmacokinetic and
pharmacodynamic properties.
14,17,18 TCI allows the user to
rapidly achieve a chosen predicted concentration without
overshooting, and both drugs can be precisely titrated in the
narrow therapeutic window between agitation and exces-
sive sedation.
6,19
Remifentanil has properties that are desirable for a sole or
adjunct conscious sedation agent, such as rapid onset and
recovery, whereas propofol provides rapid onset, rapid
recovery, and anxiolysis.
7,11,13,20,21 Although propofol and
remifentanil are suitable for providing controlled sedation
and analgesia, deep sedation can result in airway loss with
serious consequences, particularly in spontaneously breath-
ing patients.
8 To control sedation and analgesia, we adjusted
the remifentanil rates in the present study. Because the
numerical rating scale was found to be higher than 3 during
TCI remifentanil at Ce 1.5 ng/mL in 26% of the patients in
group I, we increased the remifentanil rate by 0.5 ng/mL in
these patients. However, TCI remifentanil at Ce 2 or 2.5 ng/
mL was adequate to maintain satisfactory sedation/analge-
sia. Additionally, we decreased the remifentanil rate in 9%
and 22% of patients receiving 2 and 2.5 ng/mL, respectively.
In these patients, airway support was provided with a jaw
thrust followed by brief periods of assisted mask ventila-
tion. We did not find any significant difference in the pain
scores or peripheral oxygen saturation results among the
groups, although rate adjustments were performed in the
patients with a numerical rating scale greater than 3 and an
SpO2 that was ,95%. This could be explained by the rate
(0.5 ng/mL) that we chose to use to increase or decrease the
adjustments, which could have caused such patients to be a
part of another group that had already existed in the study.
The initial TCI remifentanil and propofol rates may vary
depending on the type of anesthesia, such as conscious
sedation vs. general anesthesia. Initial remifentanil rates of
Ce 1, 1.5 and 3 ng/mL (using the Minto pharmacokinetic
model) have been utilized in combination with initial
propofol rates of Cp 0.8, 1, 2, 2.5 and 4 mg/mL in several
outpatient procedures.
4,6-8,10 In studies on oocyte retrieval,
TCI propofol without remifentanil was used at Cp 2.5 mg/
mL.
11,12 However, none of these studies have investigated
the efficacy of TCI remifentanil and propofol during oocyte
retrieval. Currently, we compared effect site TCI remifenta-
nil at 1.5, 2 and 2.5 ng/mL with 1.5 mg/mL of propofol to
find the optimal regimen for these two drugs in combina-
tion. Consequently, our study is the first study to
demonstrate that TCI remifentanil at Ce 1.5, 2 or 2.5 ng/
mL with 1.5 mg/mL of propofol provides satisfactory
conscious sedation and analgesia without hemodynamic
alterations during oocyte retrieval, assuming that rate
adjustment for TCI remifentanil is not considered an issue.
The potential limitations of our study are not selecting
objective criteria for TCI rate adjustment and not using
bispectral index monitoring. Further studies might be
Table 3 - Sedation scores and numerical rating scales.
Sedation
score First puncture 5 min 10 min Second puncture 15 min 20 min End of the procedure
Group I 2.3¡0.17 2.95¡0.17 3.13¡0.22 2.9¡0.18 3.29¡0.18 3¡0 2.83¡0.18
Group II 2.52¡0.16 3.14¡0.16 3.14¡0.23 3.17¡0.2 3.16¡0.23 3¡0 3.17¡0.15
Group III 2.52¡0.12 3.22¡0.14 3.67¡0.11 3.55¡0.1 3.44¡0.17 3.6¡0.24 3.57¡0.11
Numerical
rating scale First puncture 5 min 10 min Second puncture 15 min 20 min End of the procedure
Group I 0.22¡0.13 0.7¡0.3 1¡1 0.24¡0.17 0.57¡0.57 2¡0 0.13¡0.1
Group II 0.44¡0.44 0.29¡0.17 0.3¡0.36 0.53¡0.21 0¡00 ¡0 0.09¡0.09
Group III 0¡0 0.35¡0.19 0.28¡0.28 0.23¡0.13 0.11¡0.11 0¡00 ¡0
Data are expressed as mean ¡sem.
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814designed to vary both TCI propofol and remifentanil to
benefit from the merits of administering these pharmacolo-
gically suitable drugs, even in short procedures.
The present TCI propofol rate (Ce 1.5 mg/ml) was less than
that in both studies by Hong et al.,
11,12 in which propofol was
used without remifentanil, and the initial propofol rate was
2.5 mg/ml for oocyte retrieval. The reason why we selected a
lower propofol rate than that used in these studies was that
propofol was used in combination with remifentanil instead
of as a sole agent. Moreover, we had the opportunity to select
the effect-site mode of the latest TCI device (Base Primea),
which offers a faster onset and easier titration than the old
device (Diprifusor), which was used to administer an initial
propofol rate of 0.8 mg/mL with an initial remifentanil rate of
Ce 1 ng/ml during pregnancy termination in an observa-
tional non-randomized prospective study.
10 Using the
current three regimens, 100% of the patients completely
recovered in the recovery room 10 minutes after the
procedure in this prospective randomized study.
Nitrous oxide has been used with propofol (via
Diprifusor) at a Cp of 4 mg/mL during transvaginal
ultrasound-guided oocyte retrieval. It has been reported
that the Cp 50 values were significantly lower in patients
receiving a 50% nitrous oxide/oxygen mixture than in those
receiving a 50% oxygen/air mixture, and the pregnancy
rates were comparable between the groups.
13 No detri-
mental effects on reproductive outcomes have been found
with remifentanil and propofol.
22,23 Although the clinical
pregnancy rate was not a primary outcome of our study, we
observed comparable clinical pregnancy rates among the
groups. However, the rates we observed were almost two-
fold higher than the reported rates.
The potential for postoperative nausea and vomiting
associated with remifentanil is dose-related.
15 We observed
that 1 and 2 patients in groups II and III, respectively,
suffered from these side effects. The higher remifentanil rate
in group III did not result in a statistically significant
increase in the incidence of postoperative nausea and
vomiting. Other potential side effects of remifentanil,
including dizziness, itching and pruritus, were not observed
in our study.
In conclusion, TCI remifentanil at Ce 1.5 and 2 ng/mL
with propofol at Ce 1.5 mg/mL may be superior at providing
an earlier recovery than remifentanil at Ce 2.5 ng/mL,
although satisfactory and relatively pain-free conscious
sedation without hemodynamic parameter alterations were
achieved with all three regimens for oocyte retrieval.
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